Berkshire Asset Management’s AstraZeneca AZN Stock Holding History

Berkshire Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,283	Closed	-$971K	–	264
2025 Q4	$971K	Hold	5,283	–	–	0.04%	132
2025 Q3	$811K	Hold	5,283	–	–	0.03%	155
2025 Q2	$738K	Hold	5,283	–	–	0.03%	160
2025 Q1	$711K	Hold	5,283	–	–	0.03%	162
2024 Q4	$730K	Hold	5,283	–	–	0.03%	165
2024 Q3	$824K	Hold	5,283	–	–	0.04%	148
2024 Q2	$824K	Hold	5,283	–	–	0.04%	149
2024 Q1	$716K	Hold	5,283	–	–	0.04%	134
2023 Q4	$712K	Hold	5,283	–	–	0.04%	130
2023 Q3	$715K	Hold	5,283	–	–	0.04%	128
2023 Q2	$756K	Hold	5,283	–	–	0.04%	125
2023 Q1	$733K	Hold	5,283	–	–	0.05%	124
2022 Q4	$716K	Hold	5,283	–	–	0.05%	106
2022 Q3	$579K	Sell	5,283 -10	-0.2%	-$1.27K	0.04%	126
2022 Q2	$699K	Buy	5,293 +10	+0.2%	+$1.31K	0.05%	124
2022 Q1	$701K	Hold	5,283	–	–	0.04%	117
2021 Q4	$615K	Hold	5,283	–	–	0.04%	152
2021 Q3	$635K	Hold	5,283	–	–	0.04%	143
2021 Q2	$633K	Hold	5,283	–	–	0.04%	143
2021 Q1	$525K	Sell	5,283 -12	-0.2%	-$1.21K	0.04%	148
2020 Q4	$529K	Buy	+5,295	New	+$561K	0.04%	146
2020 Q2	–	Sell	-10,449	Closed	-$933K	–	171
2020 Q1	$933K	Buy	+10,449	New	+$984K	0.1%	105

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Berkshire Asset Management's AZN Position: Q1 2026 in Review

Berkshire Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 5,283 shares — an estimated $971K sold.

Berkshire Asset Management first reported a position in AZN in Q1 2020 and held it in 22 quarters. The position peaked at $971K in Q4 2025. 1,381 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Berkshire Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Berkshire Asset Management sold 5,283 AstraZeneca shares in Q1 2026, an estimated $971K.
Berkshire Asset Management first reported a position in AstraZeneca in Q1 2020 and held it in 22 quarters.
Berkshire Asset Management's AstraZeneca position peaked at $971K in Q4 2025.
1,381 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Berkshire Asset Management's 13F filing for Q1 2026, filed 11 May 2026.